Literature DB >> 2257134

Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus.

B Christenson1, M Böttiger.   

Abstract

Since the introduction of the measles, mumps and rubella (MMR) vaccine in Sweden in 1982, a yearly evaluation of the immunity pattern and seroconversion rate of 12-year-old children has been carried out. To be able to realize large-scale, follow-up studies, techniques have to be used which are not too labour-intensive and time-consuming but are sensitive enough to detect past immunity and post-vaccination titres. We report tests with haemolysis-in-gel (HIG) technique and an enzyme-linked, immunosorbent assay (ELISA) compared with neutralization (NT) for the detection of mumps antibodies. This study comprises 226 paired serum samples obtained between 1985 and 1989. One hundred and forty-one of the paired samples had been selected because they had given negative or borderline readings, using HIG technique. The remaining samples were consecutive pre- and post-vaccination sera obtained in 1989 from 85 vaccinees from one area in Sweden. HIG technique gave both false positive and false negative readings, compared with NT as also the false positive sera were detected. Non-inactivated sera could not be used in the NT test against mumps virus, owing to unspecific NT reactions. No differences between non-inactivated and inactivated sera by NT were seen, as against other paramyxoviruses. Cross-reactivity between mumps and parainfluenzae in NT tests was not demonstrated. The ELISA test proved more reliable and specific than HIG and was more sensitive than NT. Some post-vaccination sera from vaccinees who failed to seroconvert by NT contained high levels of mumps antibody detectable by the ELISA.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2257134     DOI: 10.1016/1045-1056(90)90009-o

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  7 in total

1.  Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus.

Authors:  J L Backhouse; H F Gidding; P B McIntyre; G L Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-07

2.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

3.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

4.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Differential durability of immune responses to measles and mumps following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland
Journal:  Vaccine       Date:  2019-02-20       Impact factor: 3.641

6.  Vaccine waning and mumps re-emergence in the United States.

Authors:  Joseph A Lewnard; Yonatan H Grad
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

7.  Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates.

Authors:  Stéphanie Ravault; Damien Friel; Emmanuel Di Paolo; Adrian Caplanusi; Paul Gillard; Michael Povey; Stephane Carryn
Journal:  J Infect Dis       Date:  2019-09-26       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.